

Date: 22-10-2018

To
Mr. BhushanMokashi
Manager
Bombay Stock Exchange Limited,
PhirozeJeeJeebhoy Towers,
Dalal Street, MUMBAI – 400 001.

Sir,

Sub: Outcome of the Board Meeting – Reg.
Ref: Our Company code no: 532041.

The following is the Outcome of the Board Meeting of the Company held on 22nd October, 2018 at 02.00 P.M. at the registered office of the Company:


- 1 The Board has approved the un-audited financial results of the company for the quarter ended on 30th September, 2018.

We are herewith enclosing un-audited financial results of the company & Limited Review Report certified by the auditor for the quarter ended 30.09.2018, as per Clause 33 (3) of SEBI (LODR) Regulations, 2015.

This is for your information and record.

Thanking you

Yours faithfully,
For **Hindustan Bio Sciences Limited**



J V R Mohan Raju
Managing Director

HINDUSTAN BIO SCIENCES LIMITED
 Plot No.31, Sagar Society, Road No.2, Banjara Hills, Hyderabad 500 034
 Phone No. 23555161, Fax 40205171
STATEMENT OF UN AUDITED RESULTS FOR THE PERIOD ENDED 30th SEPTEMBER, 2018

(Rs. in Lakhs)

Sl. No.	Particulars	Quarter ended			Half year ended		Year Ended
		30.09.2018 (unaudited)	30.06.2018 (unaudited)	30.09.2017 (unaudited)	30.09.2018 (unaudited)	30.09.2017 (unaudited)	31.03.2018 (Audited)
1	Income from Operations						
	(a) Revenue from operations	147.39	58.87	7.36	206.26	7.36	103.11
	(b) Other Income	-	-	-	-	-	9.22
	Total Revenue (1)	147.39	58.87	7.36	206.26	7.36	112.33
2	Expenses						
	(a) cost of material consumed	-	-	-	-	-	-
	(b) Purchases of Stock -in-trade	160.09	35.17	16.14	195.26	16.14	64.69
	(c) Changes in Inventories of finished goods, Stock - in-Trade and Work-in-Progress	(24.10)	7.93	(11.84)	(16.17)	(11.84)	(7.93)
	(d) Employee Benefit Expenses	5.07	4.92	5.56	9.99	11.04	22.03
	(e) Finance Costs	0.13	0.22	0.02	0.35	0.12	0.38
	(f) Selling Expenses	0.14	0.33	0.02	0.47	0.02	1.25
	(g) Depreciation and amortisation Expenses	0.27	0.26	0.22	0.53	0.45	0.96
	(h) Debit Balances Written off	-	-	-	-	-	234.96
	(h) Other Expenses	3.46	10.22	3.49	13.68	9.20	23.11
	Total Expenses(2)	145.06	59.05	13.61	204.11	25.13	339.45
3	Profit/(Loss) before Exceptional& Extraordinary items and tax (1 -2)	2.33	(0.18)	(6.25)	2.15	(17.77)	(227.12)
4	Exceptional items	-	-	-	-	-	-
5	Profit/(Loss) before tax(3 -4)	2.33	(0.18)	(6.25)	2.15	(17.77)	(227.12)
6	Tax Expenses						
	(a) Current Tax	-	-	-	-	-	-
	(b) Deferred Tax	-	-	-	-	-	(0.40)
7	Profit /(Loss) for the period from continuing operations(5-6)	2.33	(0.18)	(6.25)	2.15	(17.77)	(227.52)
8	Profit /(Loss) from discontinued operations	-	-	-	-	-	-
9	Tax Expense of discontinued operations	-	-	-	-	-	-
10	Profit /Loss from Discontinued operations after tax(8-9)	-	-	-	-	-	-
11	Profit/(Loss) for the period(7+10)	2.33	(0.18)	(6.25)	2.15	(17.77)	(227.52)
12	Other Comprehensive Income						
	A (1) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(2) income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B (1) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(2) income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
13	Total Comprehensive Income for the period (11+12) (comprising Profit (Loss) and other comprehensive income for the period	2.33	(0.18)	(6.25)	2.15	(17.77)	(227.52)
14	Paid up Equity Capital(Face value of Rs. 10/- each)	1,025.08	1,025.08	1,025.08	1,025.08	1,025.08	1,025.08
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	(819.72)
16	Earnings per equity share for continuing operations						
	(A) Basic	0.02	(0.002)	(0.06)	0.02	(0.17)	(2.22)
	(B) Diluted	0.02	(0.002)	(0.06)	0.02	(0.17)	(2.22)
17	Earnings per equity share for discontinuing operations						
	(A) Basic	-	-	-	-	-	-
	(B) Diluted	-	-	-	-	-	-
18	Earnings per equity share(for discontinuing & continuing operations						
	(A) Basic	0.02	(0.002)	(0.06)	0.02	(0.17)	(2.22)
	(B) Diluted	0.02	(0.002)	(0.06)	0.02	(0.17)	(2.22)



HINDUSTAN BIO SCIENCES LIMITED
 Plot No.31, Sagar Society, Road No.2, Banjara Hills, Hyderabad 500 034
 Phone No. 23555161,Fax 40205171
STATEMENT OF ASSETS AND LIABILITIES

Rs. In Lakhs


	PARTICULARS	As at	
		30.09.2018	31.03.2018
	ASSETS		
1	Non Current Assets (Fixed Assets)		
	Tangible Assets	5.31	5.84
	(b) Deferred Tax Asset	3.01	3.01
	(c) Long Term Loans & Advances	319.47	319.47
2	Current Assets		
	(a) Stock in Trade	24.10	7.92
	(b) Trade Receivables	117.59	31.77
	(c) Cash and Cash Equivalents	2.06	1.80
	(d) Short Term Loans and Advances	31.50	1.29
	TOTAL ASSETS	503.04	371.10
	EQUITY AND LIABILITIES		
1	Share Holders Funds		
	(a) Share Capital	1025.08	1025.08
	(b) Reserves and Surplus	(817.57)	(819.72)
	Total of Share Holders Funds	207.51	205.36
2	Non Current Liabilities		
	(a) Long Term Borrowings	174.81	76.42
	Total Non Current Liabilities	174.81	76.42
3	Current Liabilities		
	(a) Short Term Borrowings	95.82	80.67
	(b)Trade Payables	0	0
	i.Total Outstanding dues of Micro Enterprises &Small Enterprises	0	0
	ii Total Outstanding dues of Creditors other than Micro Enterprises and small enterprises	22.42	6.54
	Other Current Liabilities	0	0
	Short Term Provisions	2.48	2.11
	Sub Total -Current Liabilities	120.72	89.32
	TOTAL EQUITY AND LIABILITIES	503.04	371.10

0

Notes:

- 1 The Un Audited Financial Results were taken on record by the Board of Directors in their meeting held on 22.10.2018.
- 2 Previous Year figures have been regrouped wherever necessary.

for Hindustan Bio Sciences Limited


 J.V.R.Mohan Raju
 Managing Director



Place: Hyderabad
 Date : 22.10.2018



C. RAMACHANDRAM & CO.
CHARTERED ACCOUNTANTS

3-6-237, Unit # 606,
Lingapur La Bulide Complex,
Himayatnagar, Hyderabad - 500 029.
Ph : 23264144/45, 23223787
E-mail : crcoca@gmail.com

Limited Review Report

Review Report to
The Board of Directors
Hindustan Bio Sciences Ltd.

We have reviewed the accompanying statement of unaudited financial results of **M/s. Hindustan Bio Sciences Limited** ('the Company') for the quarter ended September 30, 2018 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulations 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, read with SEBI Circular No.CIR/CFD/FAC/62/2016 date July 05, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditors of the Entity, issued by the institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulations 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, read with SEBI Circular No.CIR/CFD/FAC/62/2016 date July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad
Date: 22.10.2018

For C.RAMACHANDRAM & Co.,
Chartered Accountants
Firm Reg No. 002864S




C.RAMACHANDRAM
Partner
M.No: 025834